Board of Directors

Murray Brennan, M.D. (Lead Director)

Emeritus Chairman of Surgery, Memorial Sloan-Kettering Cancer Center


Murray Brennan, M.D., is the emeritus chairman of Memorial Sloan-Kettering Cancer Center’s Department of Surgery and previously served as chairman since 1985. He is widely regarded as being one of the best and most famous surgeons in the world. Dr. Brennan has lectured and acted as a visiting professor throughout the world and has authored over 800 scientific papers. He has served as director of the American Board of Surgery, chairman of the American College of Surgeons Commission on Cancer, president of the Society of Surgical Oncology and president of the American Surgical Association, the oldest and most prestigious surgical association in the United States. Dr. Brennan is currently vice president of the American College of Surgeons and a member of the National Academy of Sciences. He is the recipient of numerous honors and medals for his leadership of surgery and oncology worldwide.

James A. Cannon

Chief Financial Officer and Vice Chairman, BBDO


James A. Cannon is vice chairman, chief financial officer and a member of the board of directors of BBDO Worldwide. In this capacity, he oversees the financial management of BBDO operations in 77 countries. Mr. Cannon joined BBDO in 1967, was promoted to chief financial officer of the agency in 1984, and was elected to its board of directors one year later. An integral member of the team that formed Omnicom Group via a unique three-agency merger of BBDO, DDB and Needham Harper & Steers, Mr. Cannon became comptroller of the new group and a member of its board of directors in 1986, a position he held through 2002. In 1987, he was appointed director of financial operations of the Omnicom Group, serving in this capacity until early 1989 when he rejoined BBDO Worldwide as executive vice president and chief financial officer. His return was concurrent with that of Allen Rosenshine who became chairman and chief executive officer of BBDO after heading Omnicom Group. Mr. Cannon was promoted to vice chairman of the agency in 1990. Mr. Cannon is a graduate of Pace University in the City of New York and Westchester County and served in the United States Marine Corps.

Senator Wyche Fowler, Jr.

Former U.S. Senator and Ambassador to Saudi Arabia


Senator Wyche Fowler, Jr. served for 16 years in the United States Congress. In the U.S. Senate, he served as assistant floor leader, helping mold a bipartisan consensus for major public policy issues. Senator Fowler was a member of the United States Senate Committee on Appropriations, Budget, Energy and Agriculture. First elected to the United States House of Representatives, he was a member of the Ways and Means and Foreign Affairs Committees, as well as the Select Committee on Intelligence. President Clinton appointed Senator Fowler United States ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. On his return, the FBI awarded him its highest civilian honor, the Jefferson Cup, for his assistance in combating terrorism and for helping solve terrorism crimes against the United States military in Saudi Arabia. He was named Lion of Judah by the State of Israel for successfully freeing Soviet Jew Yakov Gluzman. Senator Fowler is now engaged in an international business and law practice, and also serves as chairman of the board of the Middle East Institute, a non-profit foundation in Washington, DC.

Randal J. Kirk

Chief Executive Officer and Chairman of the Board, Intrexon Corporation


Randal J. Kirk currently serves as the chief executive officer and chairman of the board of Intrexon Corporation. In addition to his responsibilities at Intrexon, Mr. Kirk has served, since March 1999, as senior managing director and chief executive officer of Third Security, an investment management firm founded by Mr. Kirk. Additionally, Mr. Kirk founded and became chairman of the board of New River Pharmaceuticals Inc. in 1996, and served as president and chief executive officer between October 2001 and April 2007. New River Pharmaceuticals’ was acquired by Shire Plc in 2007. Mr. Kirk also currently serves as a member of the board of directors of Halozyme Therapeutics, Inc. and as chairman of the board for Clinical Data, Inc. Previously, Mr. Kirk served as a member of the board of directors of Scios, Inc., which was acquired by Johnson & Johnson, between February 2000 and May 2002. Mr. Kirk served on the board of visitors of Radford University from July 2003 to June 2009, was rector of the board from September 2006 to September 2008, and has served on the board of directors of the Radford University Foundation since September 1998. He has served on the board of visitors of the University of Virginia and Affiliated Schools since July 2009, on the Virginia Governor’s Advisory Council on Revenue Estimates since July 2006, on the Governor’s Economic Development and Jobs Creation Commission since April 2010 and served as a member of the board of directors of the Virginia University Research Partnership from July 2007 to November 2010. Mr. Kirk received a bachelor’s degree in business from Radford University and a juris doctor from the University of Virginia.

Jonathan Lewis, M.D., Ph.D.

Chief Executive Officer
ZIOPHARM Oncology, Inc.

Timothy McInerney

Partner, Riverbank Capital Securities Inc.


Timothy McInerney joined Riverbank Capital as a partner in June of 2007 specializing in financing for the biotech and specialty pharmaceutical industry. From 1992 to March 2007, Mr. McInerney was a managing director of Paramount BioCapital, Inc. where he oversaw the overall distribution of Paramount’s private equity product. Prior to 1992, Mr. McInerney was a research analyst focusing on the biotechnology industry at Ladenburg, Thalman & Co. Prior to that role, Mr. McInerney held equity sales positions at Bear Sterns & Co. and Shearson Lehman Brothers, Inc. Mr. McInerney also has worked in sales and marketing for Bristol-Myers Squibb. He received his bachelor’s degree in pharmacy from St. John’s University and also completed a post-graduate residency at the New York University Medical Center in drug information systems.

Michael Weiser, M.D., Ph.D.

Partner, Actin Biomed


Michael Weiser, M.D., Ph.D., is currently founder and co-chairman of Actin Biomed, a New York-based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the director of research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development. Dr. Weiser completed his doctorate in molecular neurobiology at the Weill Cornell Medical College, received his medical degree from New York University School of Medicine and received his bachelor’s degree in psychology from University of Vermont. He performed his post-graduate medical training in the department of obstetrics and gynecology at New York University Medical Center. Dr. Weiser also completed a postdoctoral fellowship in the department of physiology and neuroscience at New York University School of Medicine. Dr. Weiser is a member of the Alpha Omega Alpha Honor Medical Society, American Society of Clinical Oncology, American Society of Hematology and Association for Research in Vision and Ophthalmology. In addition, Dr. Weiser has received awards for both academic and professional excellence and has published extensively in both medical and scientific journals. Dr. Weiser currently serves on the board of directors of Chelsea Therapeutics International, Emisphere Technologies, Inc., and ZIOPHARM Oncology, Inc. as well as several privately held companies.